The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy

Shan-Shan Guo, Pei-Yu Huang, Qiu-Yan Chen, Huai Liu, Lin-Quan Tang, Lu Zhang, Li-Ting Liu, Ka-Jia Cao, Ling Guo, Hao-Yuan Mo, Xiang Guo, Ming-Huang Hong, Hai-Qiang Mai

BackgroundCigarette smoking is a common risk factor for developing nasopharyngeal carcinoma. However, the relationship between smoking and clinical outcomes remains uncertain.MethodsThe patients who participated in this study were drawn from a randomized clinical trial, for which the purpose was to compare the efficacy of induction chemotherapy plus concurrent chemoradiotherapy with that of induction chemotherapy plus radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. The patients who ever smoked were divided into the following categories of cumulative smoking exposure based on the duration of smoking and the quantity of cigarettes smoked: light, short-term smokers; light, long-term smokers; heavy, short-term smokers; and heavy, long-term smokers. A log-rank test and Cox models were used to assess the association between smoking and the clinical outcomes of overall survival (OS), failure-free survival (FFS), locoregional recurrence failure-free survival (LRFFS) and distant failure-free survival (DFFS).ResultsWe found that ever-smokers experienced significantly shorter LRFFS times than never-smokers (5-year LRFFS rates: 85.8% vs. 88.5%, P¿=¿0.022). The amount of smoking was significantly associated with FFS (P¿=¿0.046) and LRFFS (P¿=¿0.001) in the different ever-smoker groups. The amount of smoking was associated with LRFFS [P¿=¿0.002, HR¿=¿2.069 (95% confident interval (CI), 1.298-3.299)] even after a multivariable adjustment.ConclusionsSmoking increases the risk of locoregional recurrence. Furthermore, the amount of smoking influences the prognosis of smokers, and these effects are dose-dependent.